PAY AS LITTLE AS $0* FOR GILENYA® (fingolimod)

THERE’S A VERY GOOD CHANCE YOUR INSURANCE COVERS GILENYA, AND YOUR CO-PAY COULD BE $0*

Nothing should make you compromise on
your treatment. So, here's some good news:
GILENYA is covered by most insurance plans.†

NOT AN
ACTUAL
PATIENT.

More than 95% of people in the US with health insurance have coverage for GILENYA
More than 95% of people in the US with health insurance have coverage for GILENYA

>95% OF PEOPLE IN THE
US WITH HEALTH
INSURANCE HAVE
COVERAGE FOR
GILENYA.†

Figuring out insurance coverage is easier with the GILENYA Go Program® by your side. The Go Program can help you find out:

  • If you're eligible for a $0* co-pay

  • If you need prior authorization or approval

  • If you are eligible for any other money-saving offers

  • If you're eligible for a $0*
    co-pay

  • If you need prior authorization
    or approval

  • If you are eligible for any other
    money-saving offers

Once you're prescribed GILENYA and your health care professional submits the Start Form, you'll automatically be enrolled in the Go Program. If you are already taking GILENYA, you can receive one-on-one ongoing support, information on your medication, and educational resources.

Enroll in the Go Program right arrow

WE OFFER 2 CO-PAY
SUPPORT PROGRAMS TO
HELP YOU GET STARTED
ON—AND STAY
ON—GILENYA:

Once you're prescribed GILENYA and your health care professional submits the Start Form, the Go Program will call you to discuss your insurance coverage, check your eligibility for our co-pay support programs, and make your treatment as affordable as possible—for many, this means a $0* co-pay.

The GILENYA Prescription Co-Pay Support Program helps commercially insured patients afford treatment by reducing the cost of your co-pay to as little as $0.* We'll even send your co-pay information directly to your pharmacy.

The GILENYA Medical Co-Pay Support Program may offer support for pretests and first-dose observation.‡

On Medicare Part D? Most people on Medicare Part D pay $0 for their GILENYA prescription each month, even though they're not eligible for co-pay support. Call the Go Program for help determining what you'll pay out of pocket.

WE OFFER 2 CO-PAY
SUPPORT PROGRAMS TO
HELP
YOU GET STARTED
ON—AND STAY
ON—GILENYA:

Once you're prescribed GILENYA and your health care professional submits the Start Form, the Go Program will call you to discuss your insurance coverage, check your eligibility for our co-pay support programs, and make your treatment as affordable as possible—for many, this means a $0* co-pay.

The GILENYA Prescription Co-Pay Support Program helps commercially insured patients afford treatment by reducing the cost of your co-pay to as little as $0.* We'll even send your co-pay information directly to your pharmacy.

The GILENYA Medical Co-Pay Support Program may offer support for pretests and first-dose observation.‡

On Medicare Part D? Most people on Medicare Part D pay $0 for their GILENYA prescription each month, even though they're not eligible for co-pay support. Call the Go Program for help determining what you'll pay out of pocket.

FIND OUT IF YOU'RE
ELIGIBLE FOR
A $0 CO-PAY*!

Apply today right arrow

MAKING SURE THOSE WHO NEED OUR MEDICATIONS HAVE ACCESS TO THEM

At Novartis, we understand that you can't benefit from our medications if you can't afford them. That's why we have the following support for anyone who isn't eligible for our co-pay support programs.

  • Novartis Patient Assistance NOW helps you find patient assistance programs that can help you pay for your medications. Learn more by calling 1-800-245-5356 or by visiting www.patientassistancenow.com
  • The Novartis Patient Assistance Foundation, Inc. (NPAF) helps those who are experiencing financial hardship and have limited or no prescription coverage. To learn more about the NPAF, call the Go Program at 1-800-445-3692.
  • Novartis Patient Assistance NOW helps you find patient assistance programs that can help you pay for your medications. Learn more by calling 1-800-245-5356 or by visiting www.patientassistancenow.com
  • The Novartis Patient Assistance Foundation, Inc. (NPAF) helps those who are experiencing financial hardship and have limited or no prescription coverage. To learn more about the NPAF, call the Go Program at 1-800-445-3692.

—GILENYA COMMUNITY MEMBER

—GILENYA COMMUNITY MEMBER

GO PROGRAM is a registered trademark of Novartis AG.

*Limitations apply. Valid only for those with private insurance. The Program includes the Co-pay Card, Payment Card (if applicable), and Rebate, with a combined annual limit up to $18,000. Patient is responsible for any costs once limit is reached in a calendar year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program, (ii) where patient is not using insurance coverage at all, (iii) where the patient's insurance plan reimburses for the entire cost of the drug, or (iv) where product is not covered by patient's insurance. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations and maximums, including applicable co-payments, coinsurance, and deductibles. Program is not valid where prohibited by law. Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. Patient is responsible for complying with any applicable limitations and requirements of their health plan related to the use of the Program. Valid only in the United States and Puerto Rico. This Program is not health insurance. Program may not be combined with any third-party rebate, coupon, or offer. Proof of purchase may be required. Novartis reserves the right to rescind, revoke, or amend the Program and discontinue support at any time without notice.

†As of November 11, 2020. Novartis Pharmaceuticals Corporation does not endorse any particular plan. Check with your individual health plans.

‡Medical co-pay support for covered initial assessments/examinations or for first-dose observations (FDO) is provided without regard to whether the patient continues on with GILENYA therapy. People for whom GILENYA has been prescribed are required to report any benefits they receive under the GILENYA Medical Co-Pay Support Program to their insurance company. This offer is not valid for prescriptions and medical assessments for which payment may be made in whole or in part under federal or state health programs, including but not limited to Medicare or Medicaid, or for residents of RI. Valid only for those with commercial insurance. This program is subject to termination or modification at any time.

Important Safety Information

You should not take GILENYA if in the last 6 months you experienced heart attack, unstable angina, stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure. Do not take GILENYA if you have an irregular or abnormal heartbeat (arrhythmia), including a heart finding called prolonged QT as seen on an ECG, or if you take medicines that change your heart rhythm. Do not take GILENYA if you are allergic to fingolimod or any of the other ingredients.

Indication

GILENYA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and children 10 years of age and older.

Important Safety Information

You should not take GILENYA if in the last 6 months you experienced heart attack, unstable angina, stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure. Do not take GILENYA if you have an irregular or abnormal heartbeat (arrhythmia), including a heart finding called prolonged QT as seen on an ECG, or if you take medicines that change your heart rhythm. Do not take GILENYA if you are allergic to fingolimod or any of the other ingredients.

Indication

GILENYA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and children 10 years of age and older.

GILENYA may cause serious side effects such as:

  • Slow heart rate, especially after first dose. Adults and children will be monitored by a health care professional for at least 6 hours after the first dose or after a child takes the first dose of 0.5mg of GILENYA when switching from 0.25mg daily dose. Your pulse and blood pressure will be checked hourly. You'll get an ECG before and 6 hours after your first dose. If any heart problems arise or your heart rate is still low, you'll continue to be monitored. If you have any serious side effects, especially those that require treatment with other medicines, or if you have certain types of heart problems, or if you're taking medicines that can affect your heart, you'll be watched overnight. If you experience slow heart rate, it will usually return to normal within 1 month. Call your doctor, or seek immediate medical attention if you have any symptoms of slow heart rate, such as dizziness, tiredness, feeling like your heart is beating slowly or skipping beats, or chest pain. Symptoms can happen up to 24 hours after the first dose. Call your doctor if you miss 1 or more doses of GILENYA—you may need to repeat the 6-hour monitoring.

  • During pregnancy. Consult your doctor before getting pregnant. You should avoid becoming pregnant while taking GILENYA or in the 2 months after you stop taking it because of the risk of harm to the baby.

  • Increased risk of serious infections, some of which could be life threatening and cause death. You should not receive live vaccines during treatment with GILENYA and for 2 months after you stop taking GILENYA. Vaccines may not work as well when given during treatment with GILENYA. Because GILENYA has an increased risk of human papilloma virus (HPV), women should consult their doctor about a routine pap-smear. GILENYA lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 2 months of stopping GILENYA. Your doctor may do a blood test to check your white blood cells before you start GILENYA. Call your doctor right away if, while taking GILENYA or for 2 months after your last dose, you have fever, tiredness, body aches, chills, nausea, vomiting, or headache accompanied by fever, neck stiffness, sensitivity to light, nausea, and/or confusion. These may be symptoms of meningitis.

  • Progressive multifocal leukoencephalopathy (PML). PML is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Call your doctor right away if you have any new or worsening symptoms of PML that have lasted several days, including changes in your thinking or memory, changes in your vision, decreased strength, problems with balance, weakness on 1 side of your body, loss of coordination in your arms and legs, confusion, or changes in your personality.

  • Macular edema, a vision problem that can cause some of the same vision symptoms as an MS attack (optic neuritis), or no symptoms. If it happens, macular edema usually starts in the first 3 to 4 months after starting GILENYA. Your doctor should test your vision before you start GILENYA, 3 to 4 months after you start GILENYA, and any time you notice vision changes. Vision problems may continue after macular edema has gone away. Your risk of macular edema is higher if you have diabetes or have had an inflammation of your eye (uveitis). Call your doctor right away if you have blurriness, shadows, or a blind spot in the center of your vision; sensitivity to light; or unusually colored vision.

  • Swelling and narrowing of the blood vessels in your brain. A condition called PRES (posterior reversible encephalopathy syndrome) has happened rarely in adults taking GILENYA. Symptoms of PRES usually get better when you stop taking GILENYA. However, if left untreated, it may lead to a stroke. Call your doctor right away if you experience any symptoms, such as sudden severe headache, sudden confusion, seizures, or sudden loss of vision.

  • Liver damage. Your doctor should do blood tests to check your liver before you start GILENYA and periodically during treatment. Call your doctor right away if you have nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or if your skin or the whites of your eyes turn yellow.

  • Breathing problems. Some patients have shortness of breath. Call your doctor right away if you have trouble breathing.

  • Severe worsening of MS after stopping GILENYA. Many people who have worsening of MS symptoms after stopping GILENYA do not return to the level of function that they had before or during treatment with GILENYA. This can also occur in women stopping due to pregnancy or planning a pregnancy. This worsening happens most often within 12 weeks after stopping GILENYA, but can happen later. Do not stop taking GILENYA without talking with your doctor. Tell your doctor if you have worsening symptoms of MS after stopping GILENYA.

  • Increases in blood pressure (BP). BP should be monitored during treatment.

  • Cancers including basal, squamous, and Merkel cell carcinomas and melanoma. Tell your doctor if you have any changes in the appearance of your skin, including changes in a mole, new darkened area in your skin, a sore that does not heal, or growths on your skin such as a bump that may be shiny, pearly white, skin colored, or pink. While taking GILENYA, limit the amount of time you spend in sunlight and ultraviolet (UV) light as well as use sunscreen with a high sun protection factor and wear protective clothing. Lymphoma has also occurred in patients receiving GILENYA.

GILENYA may harm your unborn baby. Talk to your doctor if you are pregnant or planning to become pregnant. Women should stop taking GILENYA 2 months before trying to become pregnant. Women who can become pregnant should use effective birth control while on GILENYA, and for at least 2 months after stopping. If you become pregnant while taking GILENYA, or within 2 months after stopping, tell your doctor right away. It is not known if GILENYA passes into breast milk. Talk to your doctor about the best way to feed your baby if you take GILENYA. A pregnancy registry is available for women who become pregnant during GILENYA treatment. For more information, contact the GILENYA Pregnancy Registry by calling Quintiles at 1-877-598-7237, by e-mailing gpr@quintiles.com, or by going to www.gilenyapregnancyregistry.com.

Tell your doctor about all your medical conditions, including if you had or now have an irregular or abnormal heartbeat; stroke or mini-stroke; heart problems; a history of repeated fainting; a fever or infection, or if you are unable to fight infections due to a disease or are taking medicines that lower your immune system, including corticosteroids, or have taken them in the past; eye problems; diabetes; breathing or liver problems; or uncontrolled high blood pressure. Also tell your doctor if you have had chicken pox or have received the chicken pox vaccine. Your doctor may test for the chicken pox virus, and you may need to get the full course of the chicken pox vaccine and wait 1 month before starting GILENYA. Children 10 years and older should complete their vaccination schedule before starting GILENYA.

If you take too much GILENYA, call your doctor or go to the nearest hospital emergency room right away.

Tell your doctor about all the medicines you take or have recently taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

The most common side effects with GILENYA were headache, abnormal liver tests, diarrhea, cough, flu, sinusitis, back pain, abdominal pain, and pain in arms or legs.

In the pediatric study:

  • The safety in children 10 years and older receiving GILENYA was similar to that seen in adults.

  • The rate of seizures was higher in GILENYA-treated patients compared to that of a leading injectable.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.1-800-FDA-1088.

Indication

GILENYA is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults and children 10 years of age and older.

Please see full Prescribing Information, including Medication Guide.